VEGFA and age-related macular degeneration: In 2004, the FDA approved Macugen (Pegaptanib), an RNA aptamer targeting the vascular endothelial growth factor (VEGF) isoform primarily responsible for the pathologic ocular neovascularization in age-related macular degeneration (AMD) and for vascular permeability [2].